Drug Trial Radar · NCT03918278
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Jun 19, 2019
Primary completion
Jun 9, 2025
Study completion Jun 9, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemotherapy in participants with advanced tumor specific cohorts.
Conditions
- Neoplasms
Interventions
MK-0482Biological
IV infusion
pembrolizumabBiological
IV infusion
PaclitaxelDrug
IV infusion
Nab-paclitaxelDrug
IV infusion
GemcitabineDrug
IV infusion
CarboplatinDrug
IV infusion
PemetrexedDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Part 1 only)Time frame: Cycle 1 (Up to 21 days)
- Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 27 months
- Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 24 months
- Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (Part 2 only)Time frame: Up to approximately 28 days from the start of study intervention
Locations
16 sites in 8 countries. Site status is shown where the registry gives one.
Henry Ford Health System ( Site 0002)
Detroit, Michigan
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0003)
Hackensack, New Jersey
Next Oncology ( Site 0001)
San Antonio, Texas
Macquarie University ( Site 0033)
Macquarie University, New South Wales, Australia
Alfred Health ( Site 0031)
Melbourne, Victoria, Australia
BC Cancer - Vancouver Center ( Site 0010)
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre ( Site 0011)
Toronto, Ontario, Canada
FALP-UIDO ( Site 0100)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0101)
Santiago, Region M. de Santiago, Chile
Hadassa Ein Karem Medical Center ( Site 0022)
Jerusalem, Israel
Chaim Sheba Medical Center ( Site 0020)
Ramat Gan, Israel
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
Milan, Italy
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0091)
Siena, Tuscany, Italy
Seoul National University Hospital ( Site 0061)
Seoul, South Korea
Asan Medical Center ( Site 0060)
Seoul, South Korea
Hospital Clinic i Provincial ( Site 0041)
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.